Official Title
Sars-Cov2 Antibodies Response to vaccinE Against covId-19 Disease
Brief Summary

Vaccine rollout has started in many countries. In Italy, the Covid-19 vaccine used at the moment is the mRNA-based BNT162b2 and is given to Hospital employers. The investigators undertake this study to monitor IgG evolution after vaccination in the participant hospital settings, which includes 500 subjects.

Detailed Description

Vaccine rollout has started in many countries. In Italy, the Covid-19 vaccine used at the
moment is the mRNA-based BNT162b2 and is given to Hospital employers.

The investigators undertake this observational study to monitor antibody evolution after
vaccination in a hospital setting. The primary endpoint is serum IgG at the first month of
2nd jab, and at 3, 6, and 12 months afterward.

As secondary measures, nasopharyngeal swabs are included, at fortnight intervals to detects
the spike protein antigen, in the event that putative vaccine inefficacy would expose the
health personnel to Covid-19 disease with potential spreading to inpatients.

Further, clinical signs and symptoms are monitored at the weekly interval in the context of
adverse reactions/events.

Unknown status
COVID-19

Biological: BNT162b2 mRNA Covid-19 Vaccine

Hospital employers vaccinated with BNT162b2 mRNA against Sars-Cov2 are studied for serum antibody response.

Eligibility Criteria

Inclusion Criteria:

- Hospital employers vaccinated against Sars-Cov2

Exclusion Criteria:

- none

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: 80 Years
Countries
Italy
Locations

ICOT-Sapienza University Hospital
Latina, LT, Italy

Investigator: Lugi Iuliano, M.D.
Contact: +393406462332
luigi.iuliano@uniroma1.it

Contacts

Lugi Iuliano, M.D.
+393406462332
luigi.iuliano@uniroma1.it

Alessandro Polidoro, M.D.
+393478115718
alessandro.polidoro@uniroma1.it

Luigi Iuliano, M.D., Principal Investigator
University of Roma La Sapienza

ICOT University Hospital
NCT Number
Keywords
Vaccine
Covid-19
safety
SARS-CoV2
MeSH Terms
COVID-19